FDASMART, INC. VS. DISHMAN USA, INC. (L-7832-13, MIDDLESEX COUNTY AND STATEWIDE)

CourtNew Jersey Superior Court Appellate Division
DecidedApril 19, 2021
DocketA-2367-19
StatusUnpublished

This text of FDASMART, INC. VS. DISHMAN USA, INC. (L-7832-13, MIDDLESEX COUNTY AND STATEWIDE) (FDASMART, INC. VS. DISHMAN USA, INC. (L-7832-13, MIDDLESEX COUNTY AND STATEWIDE)) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
FDASMART, INC. VS. DISHMAN USA, INC. (L-7832-13, MIDDLESEX COUNTY AND STATEWIDE), (N.J. Ct. App. 2021).

Opinion

NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION This opinion shall not "constitute precedent or be binding upon any court ." Although it is posted on the internet, this opinion is binding only on the parties in the case and its use in other cases is limited. R. 1:36-3.

SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION DOCKET NO. A-2367-19

FDASMART, INC.,

Plaintiff-Appellant,

v.

DISHMAN USA, INC.,

Defendant-Respondent.

Submitted February 8, 2021 – Decided April 19, 2021

Before Judges Sabatino, Currier, and DeAlmeida.

On appeal from the Superior Court of New Jersey, Law Division, Middlesex County, Docket No. L-7832-13.

Eric J. Warner, attorney for appellant.

Holland & Knight, LLP, attorneys for respondent (Daniel Mateo and Amy McVeigh, on the brief).

PER CURIAM

In this case, before us for a second time, plaintiff FDASmart, Inc. appeals

from the trial court's post-remand November 28, 2018 order granting summary judgment to defendant Dishman U.S.A., Inc. and the February 6, 2018 order

denying reconsideration. We affirm.

Dishman Pharmaceuticals and Chemicals, LTD (DPCL) is a multinational

corporation incorporated and headquartered in India. Defendant is a New Jersey

corporation with its principal place of business in Middlesex. It is a wholly

owned subsidiary of DCPL.

In April 2013, DPCL, plaintiff, and a consulting firm –PKM1– executed a

Memorandum of Understanding (MOU) related to DPCL's desire to sell a

pharmaceutical manufacturing facility located in China and owned by DPCL's

Chinese subsidiary.

Although the first two drafts of the MOU named DPCL as the contracting

party, the final draft listed "Dishman Group" as the signatory.2 The MOU listed

DCPL's address as the address for Dishman Group and DPCL's managing

director signed the document. The MOU stated it was to be governed by and

construed in accordance with the laws of India, it required the signature of a

1 PKM is an Indian company that advises clients on mergers and acquisitions. 2 Dishman Group is not a distinct legal entity but is a marketing term that refers to DPCL and its fourteen subsidiaries. FDASmart, Inc. v. Dishman Pharm. & Chem. Ltd., 448 N.J. Super. 195, 200 n.1 (App. Div. 2016). A-2367-19 2 non-disclosure agreement in India and fees were to be paid along with applicable

Indian taxes.

Under Phase One of the MOU, plaintiff and PKM were to provide

consulting services in connection with the potential sale of the facility. Under

Phase Two, plaintiff and PKM would receive a fee of $10,000 for each letter of

intent (LOI) they secured from interested buyers who also visited the facility.

Plaintiff sent all invoices to DPCL in India for its services performed

under the MOU. It did not send any invoices, provide status updates, or

communicate in any manner with defendant.

DPCL only paid plaintiff for one of the five LOIs it submitted. On

November 7, 2013, plaintiff sent a final invoice to DPCL's India office

indicating it was owed a total of $45,800 for the four unpaid LOIs, late fees, and

legal fees. The following day, plaintiff sent a demand letter to DPCL in India

and to defendant in Middlesex, stating that if plaintiff was not compensated

before the end of the month, it would file suit in New Jersey.

In December 2013, plaintiff filed a complaint against DPCL and defendant

for breach of contract and related claims. In lieu of filing an answer, DPCL and

defendant moved to dismiss the action, asserting a lack of personal jurisdiction,

forum non conveniens, failure to state a claim against defendant, and failure to

A-2367-19 3 join PKM as a necessary party. FDASmart, 448 N.J. Super. at 200. The trial

court denied the motion without prejudice and permitted the parties to engage

in jurisdictional discovery. Ibid.

After the completion of discovery, plaintiff filed a motion for partial

summary judgment on the jurisdictional issue; DPCL and defendant opposed the

motion and renewed their motion to dismiss. Id. at 201. The trial court granted

plaintiff's partial summary judgment motion, finding that: (1) New Jersey had

general jurisdiction over DPCL and defendant and was an appropriate forum;

(2) plaintiff had stated a claim against defendant; and (3) PKM was not an

indispensable party. Ibid.

DPCL and defendant appealed. We reversed the denial of DCPL's motion

for dismissal, finding DPCL was not subject to personal jurisdiction in New

Jersey and defendant's contacts could not be imputed to DPCL under an alter

ego theory. Id. at 205. Therefore, DPCL was entitled to dismissal. Id. at 206.

We affirmed the trial court's denial of defendant's motion to dismiss, noting:

"The judge properly viewed all inferences in plaintiff's favor and found that

DPCL's managing director's signature on the MOU for the contracting party

Dishman Group was sufficient to glean an intent to bind all of DPCL's

A-2367-19 4 subsidiaries including [defendant]." Ibid. The matter was remanded for further

proceedings. Ibid.

In August 2018, both parties filed motions for summary judgment. On

November 28, 2018, the trial court issued a comprehensive written opinion

granting defendant's motion for summary judgment and denying plaintiff's

application.

The court found that defendant could not "be a party or held liable for

[DPCL]'s alleged contentions since [defendant] was never a part of the MOU

and is a separate legal entity from its parent company." He further found that

"[defendant] had no relationship with [p]laintiff . . . since [DPCL] was the only

entity involved in the . . . MOU[,]" and "[t]here [was] no evidence that the 3 -

way MOU included [defendant]." In arriving at his determination, the judge

noted DPCL's address was on the MOU, all invoices for payment under the

MOU were sent to DPCL's headquarters in India, and defendant had no

"involve[ment] in drafting or the negotiation process of the MOU and was not

even aware of it until this dispute arose."

Having concluded defendant was not a party to or liable under the MOU,

the judge found plaintiff could not sustain its claims for breach of contract or

breach of the implied covenant of good faith and fair dealing. The judge also

A-2367-19 5 dismissed plaintiff's unjust enrichment claim because defendant did not receive

any benefit from plaintiff. In dismissing plaintiff's book account and account

stated claims, the court found DPCL and defendant were separate entities and

there was "no legal nexus nor any legal theory that would make [defendant]

liable for the actions of [DPCL]."

The judge also rejected plaintiff's claim that it was entitled to sanctions

against defendant for alleged intentionally false statements made by DPCL's

managing director during his deposition. The judge concluded such a remedy

was not warranted because defendant had no liability based on the court's finding

that there was no relationship with Dishman Group. Furthermore, the alleged

misconduct was immaterial to a determination of whether defendant was bound

under the MOU; and, even if sanctions were appropriate, the judge could not

conclude the statements were intentionally false.

Thereafter, plaintiff moved for reconsideration. In an oral decision on

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cruz-Mendez v. ISU/Insurance Services
722 A.2d 515 (Supreme Court of New Jersey, 1999)
D'Atria v. D'Atria
576 A.2d 957 (New Jersey Superior Court App Division, 1990)
Verni Ex Rel. Burstein v. STEVENS, INC.
903 A.2d 475 (New Jersey Superior Court App Division, 2006)
Onderdonk v. Presbyterian Homes of NJ
425 A.2d 1057 (Supreme Court of New Jersey, 1981)
Cummings v. Bahr
685 A.2d 60 (New Jersey Superior Court App Division, 1996)
Brill v. Guardian Life Insurance Co. of America
666 A.2d 146 (Supreme Court of New Jersey, 1995)
Fdasmart, Inc. v. Dishman Pharmaceuticals (L-7832-13, Middlesex County and Statewide)
152 A.3d 948 (New Jersey Superior Court App Division, 2016)
Dontzin v. Myer
694 A.2d 264 (New Jersey Superior Court App Division, 1997)
DepoLink Court Reporting & Litigation Support Services v. Rochman
64 A.3d 579 (New Jersey Superior Court App Division, 2013)
Nicholas v. Mynster
64 A.3d 536 (Supreme Court of New Jersey, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
FDASMART, INC. VS. DISHMAN USA, INC. (L-7832-13, MIDDLESEX COUNTY AND STATEWIDE), Counsel Stack Legal Research, https://law.counselstack.com/opinion/fdasmart-inc-vs-dishman-usa-inc-l-7832-13-middlesex-county-and-njsuperctappdiv-2021.